Fundies. English
Segment disclosures
Company overviewLABORATORY CORP OF AMERICA HOLDINGS
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
40 dimension combinations 304 retained observations 60 reported periods
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Operating Segments · Othercountries · Diagnostics
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=lh:OthercountriesMember;us-gaap:StatementBusinessSegmentsAxis=lh:DiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 0 | USD | 20220225 | Open filing evidence |
Operating Segments · Europe · Diagnostics
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=srt:EuropeMember;us-gaap:StatementBusinessSegmentsAxis=lh:DiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 0 | USD | 20220225 | Open filing evidence |
Operating Segments · North America · Diagnostics
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=srt:NorthAmericaMember;us-gaap:StatementBusinessSegmentsAxis=lh:DiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 10363600000 | USD | 20220225 | Open filing evidence |
Operating Segments · Biopharma Laboratory Services
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=lh:BiopharmaLaboratoryServicesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 836200000 | USD | 20260805 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 1616800000 | USD | 20260805 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 780600000 | USD | 20260504 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 3098200000 | USD | 20260224 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 799100000 | USD | 20251031 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 2305200000 | USD | 20251031 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 784800000 | USD | 20260805 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 1506100000 | USD | 20260805 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 721300000 | USD | 20260504 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 2922600000 | USD | 20260224 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 737700000 | USD | 20251031 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 2155600000 | USD | 20251031 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 707000000 | USD | 20250801 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 1417900000 | USD | 20250801 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 710900000 | USD | 20250429 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 2774200000 | USD | 20260224 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 2697300000 | USD | 20250225 | Open filing evidence |
Operating Segments · Diagnostics
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=lh:DiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 2900700000 | USD | 20260805 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 5662800000 | USD | 20260805 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 2762100000 | USD | 20260504 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 10876500000 | USD | 20260224 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 2769600000 | USD | 20251031 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 8148000000 | USD | 20251031 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 2748800000 | USD | 20260805 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 5378400000 | USD | 20260805 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 2629600000 | USD | 20260504 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 10144300000 | USD | 20260224 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 2553500000 | USD | 20251031 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 7558100000 | USD | 20251031 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 2524900000 | USD | 20250801 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 5004600000 | USD | 20250801 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 2479700000 | USD | 20250429 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 9415100000 | USD | 20260224 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 2344700000 | USD | 20241029 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 7068300000 | USD | 20241029 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 9203500000 | USD | 20250225 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 2207600000 | USD | 20231030 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 6917100000 | USD | 20231030 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 10363600000 | USD | 20230228 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 9253400000 | USD | 20230228 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 7000100000 | USD | 20220225 | Open filing evidence |
Operating Segments · Drug Development
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=lh:DrugDevelopmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 737700000 | USD | 20241029 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 2155600000 | USD | 20241029 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 719100000 | USD | 20241029 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 2079400000 | USD | 20241029 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 666400000 | USD | 20231030 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 2048500000 | USD | 20231030 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 5845500000 | USD | 20220225 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 4877700000 | USD | 20220225 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 4578100000 | USD | 20220225 | Open filing evidence |
Operating Segments · Drug Development · Othercountries
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=lh:DrugDevelopmentMember;srt:StatementGeographicalAxis=lh:OthercountriesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 976400000 | USD | 20220225 | Open filing evidence |
Operating Segments · Drug Development · Europe
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=lh:DrugDevelopmentMember;srt:StatementGeographicalAxis=srt:EuropeMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 2050800000 | USD | 20220225 | Open filing evidence |
Operating Segments · Drug Development · North America
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=lh:DrugDevelopmentMember;srt:StatementGeographicalAxis=srt:NorthAmericaMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 2818300000 | USD | 20220225 | Open filing evidence |
CA · Covance Drug Development
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:CA;us-gaap:StatementBusinessSegmentsAxis=lh:CovanceDrugDevelopmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2019-01-01 – 2019-12-31 | 0 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 0 | USD | 20190228 | Open filing evidence |
CA · Lab Corp Diagnostics
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:CA;us-gaap:StatementBusinessSegmentsAxis=lh:LabCorpDiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2019-01-01 – 2019-12-31 | 333300000 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 342200000 | USD | 20190228 | Open filing evidence |
CH · Covance Drug Development
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:CH;us-gaap:StatementBusinessSegmentsAxis=lh:CovanceDrugDevelopmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2019-01-01 – 2019-12-31 | 532900000 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 527400000 | USD | 20190228 | Open filing evidence |
CH · Lab Corp Diagnostics
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:CH;us-gaap:StatementBusinessSegmentsAxis=lh:LabCorpDiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2019-01-01 – 2019-12-31 | 0 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 0 | USD | 20190228 | Open filing evidence |
GB · Covance Drug Development
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:GB;us-gaap:StatementBusinessSegmentsAxis=lh:CovanceDrugDevelopmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2019-01-01 – 2019-12-31 | 507900000 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 417100000 | USD | 20190228 | Open filing evidence |
GB · Lab Corp Diagnostics
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:GB;us-gaap:StatementBusinessSegmentsAxis=lh:LabCorpDiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2019-01-01 – 2019-12-31 | 0 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 21800000 | USD | 20190228 | Open filing evidence |
US · Covance Drug Development
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=lh:CovanceDrugDevelopmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2019-01-01 – 2019-12-31 | 2341800000 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 2189700000 | USD | 20190228 | Open filing evidence |
US · Lab Corp Diagnostics
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=lh:LabCorpDiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2019-01-01 – 2019-12-31 | 6662600000 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 6664300000 | USD | 20190228 | Open filing evidence |
Othercountries · Covance Drug Development
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=lh:OthercountriesMember;us-gaap:StatementBusinessSegmentsAxis=lh:CovanceDrugDevelopmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2019-01-01 – 2019-12-31 | 1195500000 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 1178900000 | USD | 20190228 | Open filing evidence |
Othercountries · Lab Corp Diagnostics
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=lh:OthercountriesMember;us-gaap:StatementBusinessSegmentsAxis=lh:LabCorpDiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2019-01-01 – 2019-12-31 | 4200000 | USD | 20200228 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 2500000 | USD | 20190228 | Open filing evidence |
Biopharma Laboratory Services · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lh:BiopharmaLaboratoryServicesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 866700000 | USD | 20261030 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 2483500000 | USD | 20261030 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 799100000 | USD | 20261030 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 2305200000 | USD | 20261030 | Open filing evidence |
Clinicaldiagnosticslaboratory
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lh:ClinicaldiagnosticslaboratoryMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2017-01-01 – 2017-12-31 | 7170500000 | USD | 20180227 | Open filing evidence |
| 2016-01-01 – 2016-12-31 | 6593900000 | USD | 20170227 | Open filing evidence |
| 2015-01-01 – 2015-12-31 | 6199300000 | USD | 20160301 | Open filing evidence |
| 2015-07-01 – 2015-09-30 | 1600900000 | USD | 20151030 | Open filing evidence |
| 2015-04-01 – 2015-06-30 | 1575000000 | USD | 20150730 | Open filing evidence |
| 2014-01-01 – 2014-12-31 | 5682200000 | USD | 20150226 | Open filing evidence |
| 2014-07-01 – 2014-09-30 | 1507300000 Restated | USD | 20151030 | Open filing evidence |
| 2014-01-01 – 2014-09-30 | 4250500000 | USD | 20141110 | Open filing evidence |
| 2014-04-01 – 2014-06-30 | 1473700000 Restated | USD | 20150730 | Open filing evidence |
| 2014-01-01 – 2014-06-30 | 2781600000 | USD | 20140729 | Open filing evidence |
| 2014-01-01 – 2014-03-31 | 1350300000 | USD | 20140429 | Open filing evidence |
| 2013-01-01 – 2013-12-31 | 5465200000 | USD | 20150226 | Open filing evidence |
| 2013-07-01 – 2013-09-30 | 1377800000 | USD | 20141110 | Open filing evidence |
| 2013-01-01 – 2013-09-30 | 4113400000 | USD | 20141110 | Open filing evidence |
| 2012-07-01 – 2013-09-30 | 1337700000 | USD | 20131028 | Open filing evidence |
| 2013-04-01 – 2013-06-30 | 1381600000 | USD | 20140729 | Open filing evidence |
| 2013-01-01 – 2013-06-30 | 2735600000 | USD | 20140729 | Open filing evidence |
| 2013-01-01 – 2013-03-31 | 1354000000 | USD | 20140429 | Open filing evidence |
| 2012-01-01 – 2012-12-31 | 5336400000 | USD | 20150226 | Open filing evidence |
| 2012-01-01 – 2012-09-30 | 4017900000 | USD | 20131028 | Open filing evidence |
| 2012-04-01 – 2012-06-30 | 1339600000 | USD | 20130730 | Open filing evidence |
| 2012-01-01 – 2012-06-30 | 2680100000 | USD | 20130730 | Open filing evidence |
| 2011-01-01 – 2011-12-31 | 5232900000 | USD | 20140225 | Open filing evidence |
Covance Drug Development
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lh:CovanceDrugDevelopmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-07-01 – 2022-09-30 | 1405800000 | USD | 20221101 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 4317000000 | USD | 20221101 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 1451900000 | USD | 20220801 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 2911200000 | USD | 20220801 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 1459300000 | USD | 20220429 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 1459500000 | USD | 20221101 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 4392900000 | USD | 20221101 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 1495200000 | USD | 20220801 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 2933400000 | USD | 20220801 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 1438200000 | USD | 20220429 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 1241900000 | USD | 20211102 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 3479400000 | USD | 20211102 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 1093700000 | USD | 20210805 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 2237500000 | USD | 20210805 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 1143800000 | USD | 20210504 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 4578100000 | USD | 20200228 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 1175400000 | USD | 20201029 | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 3376400000 | USD | 20201029 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 1126300000 | USD | 20200731 | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 2201000000 | USD | 20200731 | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 1074700000 | USD | 20200508 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 4313100000 | USD | 20200228 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 1081500000 | USD | 2019-10-31 · 20:27:27.000Z | Open filing evidence |
| 2018-01-01 – 2018-09-30 | 3214100000 | USD | 2019-10-31 · 20:27:27.000Z | Open filing evidence |
| 2018-04-01 – 2018-06-30 | 1054200000 | USD | 2019-08-08 · 20:13:14.000Z | Open filing evidence |
| 2018-01-01 – 2018-06-30 | 2132600000 | USD | 2019-08-08 · 20:13:14.000Z | Open filing evidence |
| 2018-01-01 – 2018-03-31 | 1078500000 | USD | 20190503 | Open filing evidence |
| 2017-01-01 – 2017-12-31 | 3451600000 Restated | USD | 20200228 | Open filing evidence |
| 2017-07-01 – 2017-09-30 | 867100000 Restated | USD | 20181030 | Open filing evidence |
| 2017-01-01 – 2017-09-30 | 2448700000 Restated | USD | 20181030 | Open filing evidence |
| 2017-04-01 – 2017-06-30 | 807500000 Restated | USD | 20180727 | Open filing evidence |
| 2017-01-01 – 2017-06-30 | 1581700000 Restated | USD | 20180727 | Open filing evidence |
| 2017-01-01 – 2017-03-31 | 774200000 Restated | USD | 20180501 | Open filing evidence |
| 2016-01-01 – 2016-12-31 | 3245800000 Restated | USD | 20190228 | Open filing evidence |
| 2016-07-01 – 2016-09-30 | 701100000 | USD | 20171102 | Open filing evidence |
| 2016-01-01 – 2016-09-30 | 2128300000 | USD | 20171102 | Open filing evidence |
| 2016-04-01 – 2016-06-30 | 722400000 | USD | 20170802 | Open filing evidence |
| 2016-01-01 – 2016-06-30 | 1427100000 | USD | 20170802 | Open filing evidence |
| 2016-01-01 – 2016-03-31 | 704600000 | USD | 20170428 | Open filing evidence |
| 2015-01-01 – 2015-12-31 | 2306400000 | USD | 20180227 | Open filing evidence |
| 2015-07-01 – 2015-09-30 | 669000000 | USD | 20161028 | Open filing evidence |
| 2015-01-01 – 2015-09-30 | 1613000000 | USD | 20161028 | Open filing evidence |
| 2015-04-01 – 2015-06-30 | 643700000 | USD | 20160729 | Open filing evidence |
| 2015-01-01 – 2015-06-30 | 944000000 | USD | 20160729 | Open filing evidence |
| 2015-01-01 – 2015-03-31 | 300300000 | USD | 20160506 | Open filing evidence |
| 2014-01-01 – 2014-12-31 | 173600000 | USD | 20160301 | Open filing evidence |
| 2014-01-01 – 2014-09-30 | 125000000 | USD | 20151030 | Open filing evidence |
| 2014-01-01 – 2014-06-30 | 80500000 | USD | 20150730 | Open filing evidence |
| 2014-01-01 – 2014-03-31 | 173600000 Restated | USD | 20170227 | Open filing evidence |
| 2013-01-01 – 2013-12-31 | 138900000 | USD | 20160301 | Open filing evidence |
Covance Drug Development · CA
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lh:CovanceDrugDevelopmentMember;us-gaap:StatementGeographicalAxis=country:CA| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2017-01-01 – 2017-12-31 | 0 | USD | 20180227 | Open filing evidence |
| 2016-01-01 – 2016-12-31 | 0 | USD | 20170227 | Open filing evidence |
| 2015-01-01 – 2015-12-31 | 0 | USD | 20160301 | Open filing evidence |
Covance Drug Development · CH
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lh:CovanceDrugDevelopmentMember;us-gaap:StatementGeographicalAxis=country:CH| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2017-01-01 – 2017-12-31 | 484400000 | USD | 20180227 | Open filing evidence |
| 2016-01-01 – 2016-12-31 | 450500000 | USD | 20170227 | Open filing evidence |
| 2015-01-01 – 2015-12-31 | 359700000 | USD | 20160301 | Open filing evidence |
Covance Drug Development · GB
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lh:CovanceDrugDevelopmentMember;us-gaap:StatementGeographicalAxis=country:GB| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2017-01-01 – 2017-12-31 | 272400000 | USD | 20180227 | Open filing evidence |
| 2016-01-01 – 2016-12-31 | 234100000 | USD | 20170227 | Open filing evidence |
| 2015-01-01 – 2015-12-31 | 235500000 | USD | 20160301 | Open filing evidence |
Covance Drug Development · US
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lh:CovanceDrugDevelopmentMember;us-gaap:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2017-01-01 – 2017-12-31 | 1427200000 | USD | 20180227 | Open filing evidence |
| 2016-01-01 – 2016-12-31 | 1395200000 | USD | 20170227 | Open filing evidence |
| 2015-01-01 – 2015-12-31 | 1156000000 | USD | 20160301 | Open filing evidence |
Covance Drug Development · Othercountries
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lh:CovanceDrugDevelopmentMember;us-gaap:StatementGeographicalAxis=lh:OthercountriesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2017-01-01 – 2017-12-31 | 853200000 | USD | 20180227 | Open filing evidence |
| 2016-01-01 – 2016-12-31 | 764300000 | USD | 20170227 | Open filing evidence |
| 2015-01-01 – 2015-12-31 | 555200000 | USD | 20160301 | Open filing evidence |
Diagnostics · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lh:DiagnosticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 2948900000 | USD | 20261030 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 8611700000 | USD | 20261030 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 2769600000 | USD | 20261030 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 8148000000 | USD | 20261030 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 2524900000 | USD | 20240802 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 5004600000 | USD | 20240802 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 2479700000 | USD | 20240430 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 9415100000 | USD | 20240226 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 2340800000 | USD | 20240802 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 4723600000 | USD | 20240802 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 2382800000 | USD | 20240430 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 9203500000 | USD | 20240226 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 2255400000 | USD | 20230804 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 4709500000 | USD | 20230804 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 2454100000 | USD | 20230504 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 10363600000 | USD | 20240226 | Open filing evidence |
Drug Development · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lh:DrugDevelopmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 707000000 | USD | 20240802 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 1417900000 | USD | 20240802 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 710900000 | USD | 20240430 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 2774200000 | USD | 20240226 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 699000000 | USD | 20240802 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 1360300000 | USD | 20240802 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 661300000 Restated | USD | 20240430 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 2697300000 Restated | USD | 20240226 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 677900000 | USD | 20230804 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 1382100000 | USD | 20230804 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 1459300000 | USD | 20230504 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 2860700000 Restated | USD | 20240226 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 4877700000 | USD | 20230228 | Open filing evidence |
Genomic And Esoteric Testing
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lh:GenomicAndEsotericTestingMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2016-01-01 – 2016-03-31 | 2844100000 | USD | 20180227 | Open filing evidence |
| 2015-01-01 – 2015-12-31 | 2306400000 | USD | 20180227 | Open filing evidence |
| 2014-01-01 – 2014-12-31 | 173600000 Restated | USD | 20170227 | Open filing evidence |
| 2013-01-01 – 2013-12-31 | 138900000 Restated | USD | 20160301 | Open filing evidence |
| 2012-01-01 – 2012-12-31 | 2089800000 | USD | 20150226 | Open filing evidence |
| 2011-01-01 – 2011-12-31 | 2089000000 | USD | 20140225 | Open filing evidence |
| 2010-01-01 – 2010-12-31 | 1728500000 | USD | 20130226 | Open filing evidence |
Lab Corp Diagnostics
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lh:LabCorpDiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-07-01 – 2022-09-30 | 2207600000 | USD | 20221101 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 6917100000 | USD | 20221101 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 2255400000 | USD | 20220801 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 4709500000 | USD | 20220801 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 2454100000 | USD | 20220429 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 2617500000 | USD | 20221101 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 7740800000 | USD | 20221101 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 2365500000 | USD | 20220801 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 5123300000 | USD | 20220801 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 2757800000 | USD | 20220429 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 2704200000 | USD | 20211102 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 6098800000 | USD | 20211102 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 1692700000 | USD | 20210805 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 3394700000 | USD | 20210805 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 1702000000 | USD | 20210504 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 7000100000 | USD | 20200228 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 1759200000 | USD | 20201029 | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 5242100000 | USD | 20201029 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 1760900000 | USD | 20200731 | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 3482900000 | USD | 20200731 | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 1722000000 | USD | 20200508 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 7030800000 | USD | 20200228 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 1752000000 | USD | 2019-10-31 · 20:27:27.000Z | Open filing evidence |
| 2018-01-01 – 2018-09-30 | 5336300000 | USD | 2019-10-31 · 20:27:27.000Z | Open filing evidence |
| 2018-04-01 – 2018-06-30 | 1814000000 | USD | 2019-08-08 · 20:13:14.000Z | Open filing evidence |
| 2018-01-01 – 2018-06-30 | 3584200000 | USD | 2019-08-08 · 20:13:14.000Z | Open filing evidence |
| 2018-01-01 – 2018-03-31 | 1770200000 | USD | 20190503 | Open filing evidence |
| 2017-01-01 – 2017-12-31 | 6858200000 Restated | USD | 20200228 | Open filing evidence |
| 2017-07-01 – 2017-09-30 | 1754700000 Restated | USD | 20181030 | Open filing evidence |
| 2017-01-01 – 2017-09-30 | 5115500000 Restated | USD | 20181030 | Open filing evidence |
| 2017-04-01 – 2017-06-30 | 1721100000 Restated | USD | 20180727 | Open filing evidence |
| 2017-01-01 – 2017-06-30 | 3360800000 Restated | USD | 20180727 | Open filing evidence |
| 2017-01-01 – 2017-03-31 | 1639700000 Restated | USD | 20180501 | Open filing evidence |
| 2016-01-01 – 2016-12-31 | 6307600000 Restated | USD | 20190228 | Open filing evidence |
| 2016-07-01 – 2016-09-30 | 1671800000 | USD | 20171102 | Open filing evidence |
| 2016-01-01 – 2016-09-30 | 4922100000 | USD | 20171102 | Open filing evidence |
| 2016-04-01 – 2016-06-30 | 1659700000 | USD | 20170802 | Open filing evidence |
| 2016-01-01 – 2016-06-30 | 3250300000 | USD | 20170802 | Open filing evidence |
| 2016-01-01 – 2016-03-31 | 1590600000 | USD | 20170428 | Open filing evidence |
| 2015-01-01 – 2015-12-31 | 6199300000 | USD | 20180227 | Open filing evidence |
| 2015-07-01 – 2015-09-30 | 1600900000 | USD | 20161028 | Open filing evidence |
| 2015-01-01 – 2015-09-30 | 4647900000 | USD | 20161028 | Open filing evidence |
| 2015-04-01 – 2015-06-30 | 1575000000 | USD | 20160729 | Open filing evidence |
| 2015-01-01 – 2015-06-30 | 3047000000 | USD | 20160729 | Open filing evidence |
| 2015-01-01 – 2015-03-31 | 1472000000 | USD | 20160506 | Open filing evidence |
| 2014-01-01 – 2014-12-31 | 5838000000 | USD | 20160301 | Open filing evidence |
| 2014-01-01 – 2014-09-30 | 4373900000 | USD | 20151030 | Open filing evidence |
| 2014-01-01 – 2014-06-30 | 2866600000 | USD | 20150730 | Open filing evidence |
| 2014-01-01 – 2014-03-31 | 5838000000 Restated | USD | 20170227 | Open filing evidence |
| 2013-01-01 – 2013-12-31 | 5669400000 | USD | 20160301 | Open filing evidence |
Lab Corp Diagnostics · CA
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lh:LabCorpDiagnosticsMember;us-gaap:StatementGeographicalAxis=country:CA| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2017-01-01 – 2017-12-31 | 327800000 | USD | 20180227 | Open filing evidence |
| 2016-01-01 – 2016-12-31 | 295800000 | USD | 20170227 | Open filing evidence |
| 2015-01-01 – 2015-12-31 | 290400000 | USD | 20160301 | Open filing evidence |
Lab Corp Diagnostics · CH
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lh:LabCorpDiagnosticsMember;us-gaap:StatementGeographicalAxis=country:CH| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2017-01-01 – 2017-12-31 | 0 | USD | 20180227 | Open filing evidence |
| 2016-01-01 – 2016-12-31 | 0 | USD | 20170227 | Open filing evidence |
| 2015-01-01 – 2015-12-31 | 0 | USD | 20160301 | Open filing evidence |
Lab Corp Diagnostics · GB
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lh:LabCorpDiagnosticsMember;us-gaap:StatementGeographicalAxis=country:GB| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2017-01-01 – 2017-12-31 | 29600000 | USD | 20180227 | Open filing evidence |
| 2016-01-01 – 2016-12-31 | 41800000 | USD | 20170227 | Open filing evidence |
| 2015-01-01 – 2015-12-31 | 46200000 | USD | 20160301 | Open filing evidence |
Lab Corp Diagnostics · US
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lh:LabCorpDiagnosticsMember;us-gaap:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2017-01-01 – 2017-12-31 | 6808600000 | USD | 20180227 | Open filing evidence |
| 2016-01-01 – 2016-12-31 | 6246100000 | USD | 20170227 | Open filing evidence |
| 2015-01-01 – 2015-12-31 | 5847300000 | USD | 20160301 | Open filing evidence |
Lab Corp Diagnostics · Othercountries
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lh:LabCorpDiagnosticsMember;us-gaap:StatementGeographicalAxis=lh:OthercountriesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2017-01-01 – 2017-12-31 | 4500000 | USD | 20180227 | Open filing evidence |
| 2016-01-01 – 2016-12-31 | 10200000 | USD | 20170227 | Open filing evidence |
| 2015-01-01 – 2015-12-31 | 15400000 | USD | 20160301 | Open filing evidence |
Ontario Canada
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lh:OntarioCanadaMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2012-01-01 – 2012-12-31 | 335000000 | USD | 20130226 | Open filing evidence |
| 2011-01-01 – 2011-12-31 | 309400000 | USD | 20130226 | Open filing evidence |
| 2010-01-01 – 2010-12-31 | 280000000 | USD | 20130226 | Open filing evidence |
Routine Testing
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lh:RoutineTestingMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2016-01-01 – 2016-03-31 | 6593900000 | USD | 20180227 | Open filing evidence |
| 2015-01-01 – 2015-12-31 | 6199300000 | USD | 20180227 | Open filing evidence |
| 2014-01-01 – 2014-12-31 | 5838000000 Restated | USD | 20170227 | Open filing evidence |
| 2013-01-01 – 2013-12-31 | 5669400000 Restated | USD | 20160301 | Open filing evidence |
| 2012-01-01 – 2012-12-31 | 3246600000 | USD | 20150226 | Open filing evidence |
| 2011-01-01 – 2011-12-31 | 3143900000 | USD | 20140225 | Open filing evidence |
| 2010-01-01 – 2010-12-31 | 2995400000 | USD | 20130226 | Open filing evidence |
All Other Segments
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=us-gaap:AllOtherSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2017-01-01 – 2017-12-31 | 3037200000 | USD | 20180227 | Open filing evidence |
| 2016-01-01 – 2016-12-31 | 2844100000 | USD | 20170227 | Open filing evidence |
| 2015-01-01 – 2015-12-31 | 2306400000 | USD | 20160301 | Open filing evidence |
| 2015-07-01 – 2015-09-30 | 669000000 | USD | 20151030 | Open filing evidence |
| 2015-04-01 – 2015-06-30 | 643700000 | USD | 20150730 | Open filing evidence |
| 2014-01-01 – 2014-12-31 | 329400000 | USD | 20150226 | Open filing evidence |
| 2014-07-01 – 2014-09-30 | 44500000 Restated | USD | 20151030 | Open filing evidence |
| 2014-01-01 – 2014-09-30 | 248400000 | USD | 20141110 | Open filing evidence |
| 2014-04-01 – 2014-06-30 | 42700000 Restated | USD | 20150730 | Open filing evidence |
| 2014-01-01 – 2014-06-30 | 165500000 | USD | 20140729 | Open filing evidence |
| 2014-01-01 – 2014-03-31 | 80400000 | USD | 20140429 | Open filing evidence |
| 2013-01-01 – 2013-12-31 | 343100000 | USD | 20150226 | Open filing evidence |
| 2013-07-01 – 2013-09-30 | 84400000 | USD | 20141110 | Open filing evidence |
| 2013-01-01 – 2013-09-30 | 257900000 | USD | 20141110 | Open filing evidence |
| 2012-07-01 – 2013-09-30 | 81700000 | USD | 20131028 | Open filing evidence |
| 2013-04-01 – 2013-06-30 | 86600000 | USD | 20140729 | Open filing evidence |
| 2013-01-01 – 2013-06-30 | 173500000 | USD | 20140729 | Open filing evidence |
| 2013-01-01 – 2013-03-31 | 86900000 | USD | 20140429 | Open filing evidence |
| 2012-01-01 – 2012-12-31 | 335000000 | USD | 20150226 | Open filing evidence |
| 2012-01-01 – 2012-09-30 | 248200000 | USD | 20131028 | Open filing evidence |
| 2011-01-01 – 2011-12-31 | 309400000 | USD | 20140225 | Open filing evidence |
Segment Geographical Groups Of Countries Group One
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=us-gaap:SegmentGeographicalGroupsOfCountriesGroupOneMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2013-04-01 – 2013-06-30 | 86600000 | USD | 20130730 | Open filing evidence |
| 2013-01-01 – 2013-06-30 | 173500000 | USD | 20130730 | Open filing evidence |
| 2012-04-01 – 2012-06-30 | 83800000 | USD | 20130730 | Open filing evidence |
| 2012-01-01 – 2012-06-30 | 166600000 | USD | 20130730 | Open filing evidence |